Source - LSE Regulatory
RNS Number : 0195C
BSF Enterprise PLC
08 June 2023
 

8 June 2023

 

BSF Enterprise PLC

("BSF" or the "Company")

 

US Investor Roadshow

and

Appointment of US Investor Relations Agency

 

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that it will be undertaking a US investor roadshow between June 26-30, 2023 and has appointed a US Investor Relations agency to manage its communications in the region. This follows on from the Company's successful listing on the OTCQB market, announced on 25 May 2023.

 

Trading on the OTCQB market provides BSF with access to one of the world's largest investment markets.  BSF is therefore seeking to maximise the potential of its OTCQB listing through a programme of regular, pro-active engagement with the US investment community.

 

The first step in this programme will be a US investor roadshow. The roadshow is being facilitated by Skyline Corporate Communications Group, LLC ("Skyline") and BSF will retain the services of Skyline to manage its ongoing investor relations and corporate communications activities with the US financial community. Skyline is a provider of investor relations and corporate communications services to public corporations and has offices in Boston, Massachusetts and New York City. 

In addition to the roadshow, BSF will be attending the Future Food Tech Summit in New York City on 27 and 28 June as part of its strategy to raise its profile with prospective partners and investors. The event will be attended by over 800 founders, investors and food brands pioneering alternative proteins.  More information on the event can be found here: Future Food-Tech Alternative Proteins Summit

Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues, commented: "We intend to leverage our US listing to the very best of our abilities in order to improve our international profile, increase liquidity in our shares and maximise value for all of our shareholders. This process begins with our upcoming US investor roadshow, and we look forward to expanding and developing relationships with the US investment community in the months and years ahead."

 

Further Information on Skyline Corporate Communications Group, LLC:

Skyline Corporate Communications Group, LLC is an investor relations and corporate communications firm with offices in Boston, Massachusetts and New York City. Skyline provides strategic messaging and investor communications consulting services for public companies worldwide across diverse industries and market caps. For further information visit Skyline Corporate Communications Group, LLC's website at: www.skylineccg.com.

-Ends-

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

 

BSF Enterprise PLC

 

 

Via SEC Newgate below

Che Connon - CEO & Executive Director

Geoff Baker - Executive Director

 




 

Shard Capital (Broker)


Damon Heath

Isabella Pierre                                                                   

0203 971 7000



 

SEC Newgate (Financial Communications)


Bob Huxford

Elisabeth Cowell

George Esmond

020 3757 6882

BSF@secnewgate.co.uk


 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice. 

 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUPUCPQUPWGRM
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Bsf Enterprise PLC (BSFA)

+0.23p (+4.74%)
delayed 09:03AM